A summary of the pharmacological effects of FGF21 and FGF19 analogues in humans is shown in Table 2, highlighting that both FGF19 and FGF21 analogues lower hepatic steatosis and fibrotic biomarkers in humans. The gene discussed is FGF19; the disease is Hepatic steatosis.